18 May 2018 - - Cambridge, Massachusetts-based neurological disorders treatment developer Rodin Therapeutics has appointed three senior executives with extensive experience in clinical and business development, the company said.
With their strong backgrounds in neuroscience, the new executives will accelerate Rodin's progress in developing novel therapeutics to strengthen synaptic resilience in patients with a wide array of neurological disorders.
Michael Ryan, M.D. joins Rodin as chief medical officer; Anne M. Sullivan, MBA joins as chief business officer; and Steven P. Sweeney will serve as vice president, clinical development operations.
Ryan has led clinical neuroscience research efforts at companies including Novartis and Pfizer. He comes to Rodin from Asceneuron SA, where he served as chief medical officer with full responsibility for clinical development strategy and execution.
He holds an M.D. from the Medical University of South Carolina and a B.S. from Georgetown University.
Sullivan, who has led biopharma business development and corporate strategy at Sunovion Pharmaceuticals, most recently she served as senior vice president, corporate development and operations at Sea Pharmaceuticals, Inc., a privately held biotech focused on neurological diseases. She holds an MBA from the Tuck School of Business at Dartmouth College and an A.B. from the College of the Holy Cross.
Sweeney has more than 20 years of experience at companies including Pfizer, Vertex and Annovation, and has been involved in clinical research from first-in-human Phase 1 trials through Phase 3b global registration studies. He holds a B.S. in toxicology from Northeastern University.
Rodin Therapeutics is discovering and developing first-in-class therapeutics for neurological disorders, applying unique insights into the role of epigenetics and novel chemical strategies to target specific HDAC complexes.
The company's translational strategy, along with a targeted approach to synaptic resilience, has potential across multiple phenotypically diverse diseases, such as Parkinson's disease, Alzheimer's disease, frontotemporal dementia, and traumatic brain injury, which all share the common root cause of impaired neuronal and synaptic function.